Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-01-06
1995-10-31
Ivy, C. Warren
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
549 72, 549 73, 549 75, 549 76, 549 77, 549 78, 549 79, 549484, 549488, 549491, 549496, 549498, 549499, 549500, 549501, 549502, 562426, 562429, 562430, 562432, 562439, 562442, 562451, 562452, 562455, 564 47, 564 48, 564 49, 564 50, 564 52, 564123, 564152, 564153, 564154, 564155, 564150, 564157, 564158, 568 27, 568 28, 568 33, 568 37, 568631, 568647, 568648, 568649, C07D33338, C07D30907, C07C 4302
Patent
active
054630835
ABSTRACT:
2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i,e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.
REFERENCES:
patent: 4539332 (1985-09-01), Biftu et al.
patent: 4757084 (1988-07-01), Biftu et al.
patent: 4910206 (1990-03-01), Houlihan
patent: 4916145 (1990-04-01), Tilley et al.
patent: 4959361 (1990-09-01), Walser
patent: 4987132 (1991-01-01), Mase et al.
patent: 4992428 (1991-02-01), Houlihan et al.
patent: 4996203 (1991-02-01), Biftu et al.
patent: 5001123 (1991-03-01), Biftu et al.
Biftu T., et al., "Confirmation and Activity of Tetrahydrofuran Lignans and Analogues as Specific Platelet Activating Factor Antagonists," J. Med. Chem. vol. 29, No. 10 (1986) pp. 1917-1921.
Corey, E. J., et al., "Dual Binding Modes to the Receptor for Platelet Activating Factor (PAF) of Anti-PAF Trans-2,5-Diarylfurans," Tetrahedron Letters, vol. 29, No. 24 (1988) pp. 2899-2902.
Ponpipom, M. M., et al., "(.+-.)-Trans-2-(3--Methylsulfonyl--4--Propoxyphenyl)----(3,4,5--Trimethox yphenyl)Tetrahydrofuran (L--659,989), A Novel, Potent PAF Receptor Antagonist," Biochemical and Biophysical Research Communications, vol. 150, No. 3 (1988) pp. 1213-1220.
Bartroli, J., J. Med Chem. vol. 34 (1991) pp. 3328-3334.
Carlcellar, E., et al., J. Med. Chem., vol. 35 (1992) pp. 676-683.
Crawley, G. C., "Methoxytetrahydropyrans, A New Series of Selective and Orally Potent 5--Lipoxygenase Ihibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. 2600-2609.
Musser, J. H. et al., "5--Lipoxygenase: Properties, Pharmacology, and the Quinolinyl(bridge)aryl Class of Inhibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. 2502-2524.
Guthrie, R. W., et al., "Propenyl Carboxamide Derivatives As Antagonists of Platelet Activating Factor," J. Med. Chem., vol. 33 (1990) pp. 2856-2864.
Lave, D., et al., "Pyrrolol 1,2--clThiazole Derivatives: Potent PAF Receptor Antagonists," Drugs of the Future, vol. 14, No. 9 (1989) pp. 891-898.
Ogiso, A., et al., "The Structure of Futoenone, A Novel Spiro-Cyclohexadienone Derivative," Tetrahedron Letters, No. 16, (1968) pp. 2003-2008.
Ogiso, A., et al., "The Structure and Total Synthesis of Futoenone, a Constitute of Piper Futokadzura SIEB, et ZUCC.," Chem. Pharm. Bull., vol. 18, No. 1, (1970) pp. 105-114.
Ponpipom, M. M., et al., "Structure-Activity Relationships of Kadsurenone Analogues," J. Med. Chem., J. Med. Chem., vol. 30 (1987) pp. 136-142.
shen, T. Y., "Characterization of a Platelet-Activating Factor Receptor Antagonist Isolated from Halifenteng (Piper futokadsura): Specific Inhibition of in vitro and in vivo Platelet-Activating Factor-Induced Effects," Proc. Natl. Acad. Sci. USA, vol. 82, (Feb. 1985) pp. 672-676.
Weber, K. H., et al., "Hetrazepines as Antagonists of Platelet Activating Factor," Medicinal Research Reviews, vol. 9, No. 1 (Jan. -Mar. 1989) pp. 181-218.
Hwang, S., "Specific Receptors of Platelet-Activating Factor, Receptor Heterogeneity, and Signal Transduction Mechanisms," J. Lipid Mediators, vol. 2 (1990) pp. 123-158.
McColl, S. R., "Determination of 5-Lipoxygenase Activity in Human Polymorphonuclear Leukocytes Using High-Performance Liquid Chromatography," J. Chromatography, vol. 378 (1986) pp. 44-449.
O'Donnell, M., et al., "Comparison of the Pulmonary Pharmacology of Leukotrienes and PAF; Effects of the Antagonists," Therapeutic Approaches to Inflammatory Diseases Proceedings of the Fourth International Conference of the Inflammatory Research Association, Oct. 23-27, 1988, White Haven, Pennsylvania, p. 169.
Page, C., et al., "PAF: New Antagonists, New Roles in Diseases and a Major Role in Reproductive Biology," 3rd International conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids, Tokyo, Japan, May 8-12, 1989.
Biftu Tesfaye
Cai Xiong
Grewal Gurmit
Hussion Sajjet
Shen T. Y.
Covington Raymond
CytoMed, Inc.
Ivy C. Warren
Zalesky Cheryl K.
LandOfFree
Compounds and methods for the treatment of cardiovascular, infla does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of cardiovascular, infla, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of cardiovascular, infla will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1773500